comprehensive -WSS

comprehensive

author：hotspot 2025-10-06 06:38:50 - browse：96615

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： New brain studies show LSD's effects on the brain in full color

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

How digital therapeutics firms are pivoting after Pear's bankruptcy

The 10 drugs up first for Medicare price negotiation

Stem cell treatment guidelines are released by FDA

A rare thyroid diagnosis led to unexpected, all

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

explore

comprehensive

entertainment

What does generative AI mean for health care? We asked experts

Humana sues Biden admin over Medicare Advantage audit rule

What does generative AI mean for health care? We asked experts

New brain studies show LSD's effects on the brain in full color

FDA approval of Sarepta Duchenne genetic therapy gives me hope

'Make People Better': The CRISPR babies story you probably don't know

In Memoriam: Notable people who died in 2023

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Sports medicine is finally prioritizing gender equality

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

hotspot

Illumina names Agilent executive as new CEO

EU regulator recommends expanding Mounjaro approval to obesity

Ethical issues complicate the benefits of medical crowdfunding

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

House transparency, PBM reform bill gains bipartisan support

Covid hospitalizations on the rise, Humana says

entertainment

hotspot

focus

hotspot